nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Peripheral vascular disorder—Varenicline—nicotine dependence	0.0667	0.0708	CcSEcCtD
Alprostadil—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.0499	0.053	CcSEcCtD
Alprostadil—Fungal infection—Varenicline—nicotine dependence	0.0423	0.045	CcSEcCtD
Alprostadil—Mydriasis—Varenicline—nicotine dependence	0.041	0.0435	CcSEcCtD
Alprostadil—Accidental injury—Varenicline—nicotine dependence	0.0369	0.0393	CcSEcCtD
Alprostadil—Hyperkalaemia—Varenicline—nicotine dependence	0.0321	0.0341	CcSEcCtD
Alprostadil—Influenza like illness—Varenicline—nicotine dependence	0.0317	0.0337	CcSEcCtD
Alprostadil—Diabetes mellitus—Varenicline—nicotine dependence	0.0273	0.029	CcSEcCtD
Alprostadil—Injury—Varenicline—nicotine dependence	0.0258	0.0274	CcSEcCtD
Alprostadil—Hypoglycaemia—Varenicline—nicotine dependence	0.0243	0.0258	CcSEcCtD
Alprostadil—Lethargy—Varenicline—nicotine dependence	0.0242	0.0257	CcSEcCtD
Alprostadil—Hypokalaemia—Varenicline—nicotine dependence	0.0216	0.0229	CcSEcCtD
Alprostadil—Bronchitis—Varenicline—nicotine dependence	0.0197	0.021	CcSEcCtD
Alprostadil—Pollakiuria—Varenicline—nicotine dependence	0.0189	0.0201	CcSEcCtD
Alprostadil—Hyperglycaemia—Varenicline—nicotine dependence	0.0185	0.0197	CcSEcCtD
Alprostadil—Acute coronary syndrome—Varenicline—nicotine dependence	0.018	0.0192	CcSEcCtD
Alprostadil—Myocardial infarction—Varenicline—nicotine dependence	0.0179	0.019	CcSEcCtD
Alprostadil—Sinusitis—Varenicline—nicotine dependence	0.0172	0.0182	CcSEcCtD
Alprostadil—Bradycardia—Varenicline—nicotine dependence	0.0167	0.0178	CcSEcCtD
Alprostadil—Hypoaesthesia—Varenicline—nicotine dependence	0.0163	0.0174	CcSEcCtD
Alprostadil—Urethral disorder—Varenicline—nicotine dependence	0.0161	0.0171	CcSEcCtD
Alprostadil—Visual impairment—Varenicline—nicotine dependence	0.0158	0.0168	CcSEcCtD
Alprostadil—Erythema—Varenicline—nicotine dependence	0.0143	0.0152	CcSEcCtD
Alprostadil—Back pain—Varenicline—nicotine dependence	0.0138	0.0147	CcSEcCtD
Alprostadil—Muscle spasms—Varenicline—nicotine dependence	0.0137	0.0146	CcSEcCtD
Alprostadil—Anaemia—Varenicline—nicotine dependence	0.0132	0.014	CcSEcCtD
Alprostadil—Syncope—Varenicline—nicotine dependence	0.0128	0.0136	CcSEcCtD
Alprostadil—Loss of consciousness—Varenicline—nicotine dependence	0.0126	0.0133	CcSEcCtD
Alprostadil—Cough—Varenicline—nicotine dependence	0.0125	0.0132	CcSEcCtD
Alprostadil—Convulsion—Varenicline—nicotine dependence	0.0124	0.0132	CcSEcCtD
Alprostadil—Hypertension—Varenicline—nicotine dependence	0.0123	0.0131	CcSEcCtD
Alprostadil—Discomfort—Varenicline—nicotine dependence	0.012	0.0128	CcSEcCtD
Alprostadil—Dry mouth—Varenicline—nicotine dependence	0.0119	0.0126	CcSEcCtD
Alprostadil—Oedema—Varenicline—nicotine dependence	0.0117	0.0124	CcSEcCtD
Alprostadil—Infection—Varenicline—nicotine dependence	0.0116	0.0123	CcSEcCtD
Alprostadil—Shock—Varenicline—nicotine dependence	0.0115	0.0122	CcSEcCtD
Alprostadil—Thrombocytopenia—Varenicline—nicotine dependence	0.0114	0.0121	CcSEcCtD
Alprostadil—Tachycardia—Varenicline—nicotine dependence	0.0114	0.0121	CcSEcCtD
Alprostadil—Skin disorder—Varenicline—nicotine dependence	0.0113	0.012	CcSEcCtD
Alprostadil—Hyperhidrosis—Varenicline—nicotine dependence	0.0113	0.012	CcSEcCtD
Alprostadil—Hypotension—Varenicline—nicotine dependence	0.0109	0.0116	CcSEcCtD
Alprostadil—Dyspepsia—Varenicline—nicotine dependence	0.0103	0.0109	CcSEcCtD
Alprostadil—Pain—Varenicline—nicotine dependence	0.00997	0.0106	CcSEcCtD
Alprostadil—Feeling abnormal—Varenicline—nicotine dependence	0.00961	0.0102	CcSEcCtD
Alprostadil—Body temperature increased—Varenicline—nicotine dependence	0.00922	0.0098	CcSEcCtD
Alprostadil—Abdominal pain—Varenicline—nicotine dependence	0.00922	0.0098	CcSEcCtD
Alprostadil—Asthenia—Varenicline—nicotine dependence	0.00837	0.00889	CcSEcCtD
Alprostadil—Pruritus—Varenicline—nicotine dependence	0.00825	0.00877	CcSEcCtD
Alprostadil—Diarrhoea—Varenicline—nicotine dependence	0.00798	0.00848	CcSEcCtD
Alprostadil—Dizziness—Varenicline—nicotine dependence	0.00771	0.00819	CcSEcCtD
Alprostadil—Rash—Varenicline—nicotine dependence	0.00735	0.00781	CcSEcCtD
Alprostadil—Dermatitis—Varenicline—nicotine dependence	0.00735	0.00781	CcSEcCtD
Alprostadil—Headache—Varenicline—nicotine dependence	0.00731	0.00776	CcSEcCtD
Alprostadil—Nausea—Varenicline—nicotine dependence	0.00693	0.00736	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—TAS2R16—nicotine dependence	0.00288	0.0489	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00194	0.0331	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—TAS2R16—nicotine dependence	0.00194	0.0331	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00186	0.0316	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00163	0.0277	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00159	0.0271	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00159	0.027	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00151	0.0256	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—TAS2R16—nicotine dependence	0.00148	0.0251	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00134	0.0229	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—FGD1—nicotine dependence	0.00128	0.0217	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00126	0.0214	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00126	0.0214	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—OPRM1—nicotine dependence	0.00121	0.0206	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—FGD1—nicotine dependence	0.00116	0.0197	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00115	0.0196	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0011	0.0187	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.0011	0.0187	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00108	0.0183	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00108	0.0183	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—TAS2R16—nicotine dependence	0.000998	0.017	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000998	0.017	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000908	0.0154	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000908	0.0154	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—DRD2—nicotine dependence	0.000877	0.0149	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000873	0.0148	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TAS2R16—nicotine dependence	0.000873	0.0148	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—FGD1—nicotine dependence	0.000862	0.0147	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—FGD1—nicotine dependence	0.000862	0.0147	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000834	0.0142	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—OPRM1—nicotine dependence	0.00082	0.0139	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—OPRM1—nicotine dependence	0.00082	0.0139	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—FGD1—nicotine dependence	0.000783	0.0133	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—FGD1—nicotine dependence	0.000783	0.0133	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000778	0.0132	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000778	0.0132	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—OPRM1—nicotine dependence	0.000686	0.0117	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGD1—nicotine dependence	0.000685	0.0116	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—OPRM1—nicotine dependence	0.000623	0.0106	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKR1B10—nicotine dependence	0.000605	0.0103	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—DRD2—nicotine dependence	0.000593	0.0101	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—DRD2—nicotine dependence	0.000593	0.0101	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TAS2R16—nicotine dependence	0.00059	0.01	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TAS2R16—nicotine dependence	0.00059	0.01	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000578	0.00983	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKR1B10—nicotine dependence	0.000502	0.00853	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—DRD2—nicotine dependence	0.000496	0.00843	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—OPRM1—nicotine dependence	0.000463	0.00788	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000463	0.00788	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGD1—nicotine dependence	0.000463	0.00787	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGD1—nicotine dependence	0.000463	0.00787	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—DRD2—nicotine dependence	0.00045	0.00766	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—WASF2—nicotine dependence	0.000426	0.00725	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—OPRM1—nicotine dependence	0.000421	0.00715	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—OPRM1—nicotine dependence	0.000421	0.00715	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKR1B10—nicotine dependence	0.000409	0.00695	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKR1B10—nicotine dependence	0.000409	0.00695	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—WASF1—nicotine dependence	0.000409	0.00695	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP2A7—nicotine dependence	0.000391	0.00664	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—OPRM1—nicotine dependence	0.000368	0.00626	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—DRD2—nicotine dependence	0.000335	0.00569	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—DRD2—nicotine dependence	0.000335	0.00569	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—DRD2—nicotine dependence	0.000304	0.00517	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—DRD2—nicotine dependence	0.000304	0.00517	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—WASF2—nicotine dependence	0.000288	0.00489	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—WASF2—nicotine dependence	0.000288	0.00489	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—WASF1—nicotine dependence	0.000276	0.00469	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—WASF1—nicotine dependence	0.000276	0.00469	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DRD2—nicotine dependence	0.000266	0.00452	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—OPRM1—nicotine dependence	0.000249	0.00423	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—OPRM1—nicotine dependence	0.000249	0.00423	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DRD2—nicotine dependence	0.00018	0.00305	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DRD2—nicotine dependence	0.00018	0.00305	CbGpPWpGaD
